All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, July 7, 2022
Home » Authors » Amanda Pedersen

Amanda Pedersen

Articles

ARTICLES

Grim future for device start-ups as investors flee to other markets

Dec. 27, 2016
By Amanda Pedersen
No Comments

Abbott ready to bolt on Alere based on 'damaging business developments'

Dec. 9, 2016
By Amanda Pedersen
No Comments
After nearly 10 months of waffling on a $5.8 billion decision, Abbott Laboratories might have spotted an emergency exit from its contract to buy Alere Inc. "Alere is no longer the company Abbott agreed to buy 10 months ago," said Scott Stoffel, divisional vice president of external communications at Abbott. The company cited a series of what it called "damaging business developments" that Alere has suffered since the agreement was signed in late January. Alere lost its billing privileges for a substantial division, has suffered a permanent recall of an important product platform, has...
Read More

Augmedix secures $23M to boost Smartglass-based scribe service

Dec. 9, 2016
By Amanda Pedersen
No Comments
A common assumption about the rise of digital health care is that technology makes medical practice less human, but some start ups are proving the contrary to be true. One such company, San Francisco-based Augmedix Inc., developed a remote scribe service based on Google Glass that is intended to re-humanize the doctor-patient relationship by eliminating the time physicians spend on mandated electronic health care documentation.
Read More

Abbott ready to bolt on Alere based on 'damaging business developments'

Dec. 8, 2016
By Amanda Pedersen
No Comments
After nearly 10 months of waffling on a $5.8 billion decision, Abbott Laboratories might have spotted an emergency exit from its contract to buy Alere Inc.
Read More

Illumina spin-off launches massive study in search of cancer's 'Holy Grail'

Dec. 7, 2016
By Amanda Pedersen
No Comments
A liquid biopsy company that spun out of Illumina Inc. in January to search for what it considers the holy grail of oncology – a blood test capable of detecting cancer at the earliest, most curable, stages – recently took a big first step toward that end. Grail Inc., of Menlo Park, Calif., launched a study that will eventually include up to four-dozen U.S. sites tasked with analyzing blood and tissue samples from 10,000 patients in an effort to characterize the landscape of cell-free DNA profiles in both cancer and non-cancer patients using a...
Read More

Illumina spin-off launches massive study in search of cancer's 'Holy Grail'

Dec. 6, 2016
By Amanda Pedersen
No Comments
A liquid biopsy company that spun out of Illumina Inc. in January to search for what it considers the holy grail of oncology – a blood test capable of detecting cancer at the earliest, most curable, stages – recently took a big first step toward that end.
Read More

GE and Boston Children's collaboration targets childhood brain diseases

Nov. 29, 2016
By Amanda Pedersen
No Comments

Apama steers new balloon catheter toward next phase

Nov. 23, 2016
By Amanda Pedersen
No Comments

Heartmate 3 data may unravel LVAD riddle

Nov. 21, 2016
By Amanda Pedersen
No Comments
Pump thrombosis has been such a well-established shortcoming of left ventricular assist devices (LVADs), that one heart surgeon went so far as to borrow Winston Churchill's phraseology to describe it as "a riddle, wrapped in a mystery, inside an enigma" for the title of his September 2014 article in the Annals of Cardiothoracic Surgery. But St. Jude Medical Inc. may have unraveled that riddle with its Heartmate 3 LVAD system. According to short-term results of the company's U.S. pivotal study, MOMENTUM 3, there were no cases of pump thrombosis in patients implanted with the...
Read More

Heartmate 3 data may unravel LVAD riddle

Nov. 21, 2016
By Amanda Pedersen
No Comments
Pump thrombosis has been such a well-established shortcoming of left ventricular assist devices (LVADs), that one heart surgeon went so far as to borrow Winston Churchill's phraseology to describe it as "a riddle, wrapped in a mystery, inside an enigma" for the title of his September 2014 article in the Annals of Cardiothoracic Surgery. But St. Jude Medical Inc. may have unraveled that riddle with its Heartmate 3 LVAD system.
Read More
View All Articles by Amanda Pedersen

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 6, 2022.
  • Novavax-COVID-19-vaccine-vial

    Novavax vaccine shows its chops

    BioWorld
    Given that Novavax Inc.’s COVID-19 vaccine will be a latecomer to the U.S. scene if it gets FDA authorization, it’s been cast in a supporting role to the lead...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for July 6.
  • Blood sample, DNA

    Biomarin outlines pricing strategy for costly hemophilia A gene therapy after backing from European regulators

    BioWorld
    The first gene therapy to treat severe hemophilia A was among the drugs recommended for European approval by regulators from the EMA’s CHMP at its monthly...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing